Tonsillar immunology in IgA nephropathy

Yang, Xinxin; Zhu, Anchao; Meng, Hongxue

doi:10.1016/j.prp.2020.153007

Cited by 6 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, recent reviews describe that immunological evidence supporting the usefulness of tonsillectomy as a treatment for IgAN is gradually accumulating. 29,30 Moreover, there is a report about the randomized controlled trial of tonsillectomy in patients with IgAN other than Japanese. 31 Thus, we considered that our result could be increasingly applied to patients with IgAN in future.…”

Section: Discussionmentioning

confidence: 99%

Cost Analysis of Screening for IgA Nephropathy Using Novel Biomarkers

Ishida

Matsuzaki

Itoh

et al. 2022

Value in Health Regional Issues

View full text Add to dashboard Cite

Objectives: IgA nephropathy (IgAN) is the most common primary chronic glomerulonephritis and a major cause of end-stage kidney disease worldwide. Novel biomarkers, including the aberrantly glycosylated IgA1 and glycan-specific antibodies, could be useful in the diagnosis of IgAN. The aim of this study was to assess the cost analysis of IgAN screening using novel biomarkers in addition to the conventional screening compared with conventional screening alone.Methods: To estimate the medical expense of each strategy related to renal disease for 40 years, we developed an analytical decision model. The decision tree started at "40 years of age with first-time hematuria." It simulated 2 clinical strategies: IgAN screening using the novel biomarkers (group N) and conventional screening (group C). The analysis results were presented as medical expenses from a societal perspective. Discounting was not conducted. Results:The expected medical expense per person for 40 years was U31.2 million (~$291 000) in group N and U33.4 million (~$312 000) in group C; hence, expense in group N was lower by U2.2 million (~$21 000). In group N, the expected value of IgAN increased by 5.67% points (N 48.44%, C 42.77%) and that of dialysis introduction decreased by 0.85% points (N 19.06%, C 19.91%). In the sensitivity analysis, expenses could be reduced in almost all cases except when renal biopsy using conventional screening was performed at the rate of 73% or higher. Conclusion:Screening for IgAN using novel biomarkers would reduce renal disease-related expenses.

show abstract

Section: Discussionmentioning

confidence: 99%

Cost Analysis of Screening for IgA Nephropathy Using Novel Biomarkers

Ishida

Matsuzaki

Itoh

et al. 2022

Value in Health Regional Issues

View full text Add to dashboard Cite

show abstract

“…Its clinical manifestations include proteinuria, hematuria, acute kidney injury, hypertriglyceridemia, and hypertension. IgAN is the main cause of end-stage renal disease in patients with primary glomerular disease in China ( Yang et al, 2020 ). Although clinical manifestations vary, the majority of patients with IgAN exhibit progressive symptoms, with progression to end-stage renal disease within 10 years after diagnosis in 10–30% of cases ( Liu et al, 2018 ).…”

Section: Introductionmentioning

confidence: 99%

Modified Huangqi Chifeng Decoction Attenuates Proteinuria by Reducing Podocyte Injury in a Rat Model of Immunoglobulin a Nephropathy

Chang

Yang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Modified Huangqi Chifeng decoction (MHCD) has been used to reduce proteinuria in immunoglobulin A nephropathy (IgAN) for many years. Previously, we have demonstrated its protective role in glomerular mesangial cells. Podocyte injury, another key factor associated with proteinuria in IgAN, has also attracted increasing attention. However, whether MHCD can reduce proteinuria by protecting podocytes remains unclear. The present study aimed to investigate the protective effects of MHCD against podocyte injury in a rat model of IgAN. To establish the IgAN model, rats were administered bovine serum albumin, carbon tetrachloride, and lipopolysaccharide. MHCD in three doses or telmisartan was administered once daily for 8 weeks (n = 10 rats/group). Rats with IgAN developed proteinuria at week 6, which worsened over time until drug intervention. After drug intervention, MHCD reduced proteinuria and had no effect on liver and kidney function. Furthermore, MHCD alleviated renal pathological lesions, hyperplasia of mesangial cells, mesangial matrix expansion, and podocyte foot process fusion. Western blot analysis revealed that MHCD increased the expression of the podocyte-associated proteins nephrin and podocalyxin. Additionally, we stained podocyte nuclei with an antibody for Wilms’ tumor protein one and found that MHCD increased the podocyte number in rats with IgAN. In conclusion, these results demonstrate that MHCD attenuates proteinuria by reducing podocyte injury.

show abstract